



The association of smoking status with glycemic control, metabolic profile and diabetic complications– Results of the Australian National Diabetes Audit (ANDA)

N. Szwarcbard^a, M. Villani^{a,b}, A. Earnest^a, J. Flack^{c,d,e}, S. Andrikopoulos^{f,g}, N. Wischer^h, G. Soldatos^{a,i}, D. Gasevic^{a,j}, S. Zoungas^{a,i,*}

^a School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, 3004, Australia

^b Research and Evaluation, Ambulance Victoria, Blackburn, VIC 3130, Australia,

^c Department of Diabetes and Endocrinology, Bankstown-Lidcombe Hospital, Bankstown, NSW 2200, Australia

^d Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia

^e School of Medicine, Western Sydney University, Sydney, NSW, Australia

^f Department of Medicine, University of Melbourne, Parkville, VIC 3010, Australia

^g Australian Diabetes Society, Sydney, NSW 2000, Australia

^h National Association of Diabetes Centres, Sydney, NSW, 2000, Australia

ⁱ Diabetes and Vascular Medicine Unit, Monash Health, Clayton, VIC, Australia, 3168

^j Usher Institute, University of Edinburgh, Teviot Place, Edinburgh EH8 9AG, United Kingdom

ARTICLE INFO

Article history:

Received 3 March 2020

Received in revised form 13 May 2020

Accepted 13 May 2020

Available online 20 May 2020

Keywords:

Diabetes

Smoking

HbA_{1c}

Microvascular

Macrovascular

Complications

ABSTRACT

Background: Tobacco smoking and diabetes mellitus contribute significantly to the overall health burden and mortality of Australians. We aimed to assess the relationship of smoking with glycemic control, metabolic profile and complications in Australian patients living with diabetes.

Methods: We analysed the 2011–2017 biennial Australian National Diabetes Audit cross-sectional data. Patients were classified as current, past or never smokers. Linear (or quantile) and logistic regression models were used to assess for associations.

Results: Data from 15,352 patients were analysed, including 72.2% with type 2 diabetes. Current smokers comprised 13.5% of the study population. Current and past smokers had a median HbA_{1c} that was 0.49% and 0.14% higher than never smokers, respectively, as well as higher triglyceride and lower HDL levels (all *p* values < .0001). Compared to never smokers, current smokers had higher odds of severe hypoglycemia and current and past smokers had higher odds of myocardial infarction, stroke, peripheral vascular disease, lower limb amputation, erectile dysfunction and peripheral neuropathy (all *p* values ≤.001), with no significant change over time.

Conclusion: When compared to never smokers, current and past smokers had poorer glycemic and lipid control and higher odds of macrovascular and microvascular complications. Despite this, current smoking remains prevalent among Australians with diabetes.

© 2020 Elsevier Inc. All rights reserved.

Abbreviations: ACE, Angiotensin-Converting Enzyme; ARB, Angiotensin II Receptor Blocker; ANDA, Australian National Diabetes Audit; ANOVA, Analysis of Variance; aOR, Adjusted Odds Ratio; AQCA, Australian Quality Clinical Audit; AQSMA, Australian Quality Self-Management Audit; BMI, Body Mass Index; BP, Blood Pressure; CABG, Coronary Artery Bypass Graft; CKD, Chronic Kidney Disease; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; DDP-4, Dipeptidyl Peptidase-4; eGFR, Estimated Glomerular Filtration Rate; ESKD, End Stage Kidney Disease; GLP-1, Glucagon Like Peptide 1; HbA_{1c}, Haemoglobin A1C; HDL, High Density Lipoprotein; IQR, Interquartile Range; LDL, Low Density Lipoprotein; NADC, National Association of Diabetes Centre; SGLT2, Sodium-GlucoseCo-Transporter 2; T1DM, Type 1 Diabetes Mellitus; T2DM, Type 2 Diabetes Mellitus.

* Corresponding author at: School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC 3004, Australia.

E-mail address: sophia.zoungas@monash.edu (S. Zoungas).

1. Background

Diabetes mellitus is a major public health challenge in Australia. An estimated 1.2 million (6%) Australian adults are affected by diabetes, with approximately 85% representing type 2 diabetes (T2DM) and 10% with type 1 diabetes (T1DM).^{1,2} In 2015, diabetes was estimated to contribute to over 1 million hospitalisations per year and 10% of all deaths in Australia.^{2,3} Diabetes also places a substantial economic burden on the Australian population, with over \$14.5 billion dollars spent on diabetes-related health expenditure annually.⁴

Tobacco smoking was estimated to be responsible for 9.3% of the disease burden in Australia in 2015; the leading risk factor for both chronic

disease and death. In Australia in 2015 it was estimated that smoking contributed to almost 21,000 deaths (13.3% of all deaths), with the most common underlying cause of death being chronic obstructive pulmonary disease, lung cancer, coronary heart disease or stroke.⁵ Globally, smoking contributed to over seven million deaths in 2017.⁶

Nicotine deleteriously alters glucose homeostasis through a number of mechanisms, including impaired β cell function, increased insulin resistance^{7–9} and hormonally-mediated hyperglycemia.^{10,11} As such, tobacco smoking has been causally linked with an increased risk of developing type 2 diabetes, which has been observed in a dose-dependent manner and seen in both active and passive smoking.^{7,12,13} The 2014 Surgeon General's report on the health consequences of smoking, estimated the risk of developing diabetes to be 30–40% higher in smokers than in never smokers.¹⁴ This increased risk was reported to be abrogated or reversed by smoking cessation, such that long-term quitters (>10 years) have a risk almost equivalent to that of the general population.^{14,15} People with diabetes who smoke have worse glycemic control than non-smokers. This may manifest as either hyperglycemia and its associated complications, with a substantially increased risk of cardiovascular disease (up to 50% greater than that of never smokers) and increased all-cause mortality,^{14,16} or as an increased risk of severe hypoglycemia.¹⁷

Guidelines impress the importance of both promoting smoking cessation as a key public health issue in order to control the ever-expanding epidemic of diabetes worldwide,¹⁴ and also as an essential standard of care in the management of people with diabetes.^{15,16,18} However, efforts to understand contemporary rates of smoking among people with diabetes in Australia and the relationship between smoking and complications, have not yet been reported.

In this study, we aimed to examine the association of smoking status with glycemic control, metabolic profile and diabetic complications among over 15,000 adults living with diabetes in Australia, and to monitor the change in these trends over recent years.

2. Methods

2.1. Study design, setting and patients

We conducted an observational, cross-sectional study using the Australian National Diabetes Audit (ANDA) data.

ANDA is an annual, de-identified, cross-sectional audit performed by over 50 primary, secondary and tertiary health care services throughout Australia. It is facilitated by the National Association of Diabetes Centres (NADC) – a division of the Australian Diabetes Society, with funding provided by the Australian Government Department of Health and Ageing. The data provide both Australian-wide and facility specific information on diabetes management, diabetes-related complications and the overall wellbeing of patients who are attending diabetes services across every state and territory in Australia. The audit aims to deliver an important basis for quality improvement initiatives in the ongoing multifaceted care of diabetes.¹⁹

ANDA involves data collection over a consecutive four-week period in May to June each year, with an alternating biennial focus on either self-management and quality of life (Australian Quality Self-Management Audit – AQSMa) or clinical management indicators (Australian Quality Clinical Audit – AQCA). In brief, participation is voluntary and formal invitations to participate are sent to all centres registered with the NADC and other interested primary care, community-based or specialist healthcare providers in private practice. Unique site codes are allocated to allow data collection, handling and analysis to be undertaken in a double-blind fashion. Over four weeks (either during May or June) clinicians complete either an electronic or hard copy data collection form for all consecutive patients reviewed at a participating centre. Data were collected during the standard medical consultation by the treating health professional who reviewed medical records and available pathology, in discussion with the patient.²⁰ The data collection form involves a single page

minimal dataset including patient demographics, diabetes history and management, anthropometric measurements, comorbidities and diabetic complications (Supplementary Fig. 1).

For the purposes of this study, data were pooled from four consecutive biennial ANDA-AQCA audits: 2011, 2013, 2015 and 2017. All adults with type 1 diabetes, type 2 diabetes and diabetes due to unknown or other aetiologies were included in this study. Those with gestational diabetes and those aged under 18 years were excluded. Given the focus of the effect of smoking in this study, those without information regarding smoking status were excluded.

Ethics approval for our study was provided by the Monash Health Human Research Ethics Committee (Monash Health Reference: RES-17-0000-164L).

2.2. Dependent variable

The pre-specified dependent variable was self-reported smoking status – with never smokers including patients who reported never smoking regularly for longer than a one-month period, past smokers including patients who reported no regular smoking in the preceding one month and current smokers including patients who reported regular smoking.

2.3. Independent variables

Pre-specified independent variables included glycemic control (glycated haemoglobin – HbA_{1c} (%), severe hypoglycemia (defined by a history of having ever had an episode of severe hypoglycemia requiring the assistance of another person) and number of glucose lowering therapies), microvascular complications (retinopathy, peripheral neuropathy, advanced chronic kidney disease (CKD), microalbuminuria, macroalbuminuria and erectile dysfunction), macrovascular complications (peripheral vascular disease, myocardial infarction, coronary artery revascularisation, cerebral stroke, foot ulceration and lower limb amputation), body mass index (BMI) and blood pressure (systolic and diastolic blood pressure).

The most recent pathology results from patients were recorded and included HbA_{1c} (% or mmol/mol), serum creatinine (μ mol/L) and lipid profile (total cholesterol, low density lipoprotein (LDL), high density lipoprotein (HDL) and triglycerides – all mmol/L) – including both fasting and non-fasting values, depending on availability. Given the large number of services that provided the pathology collected, laboratory values across centres were not able to be standardised. An estimated glomerular filtration rate (eGFR) was calculated using age, sex and serum creatinine as per the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula (Supplementary 1).²¹

Advanced CKD was defined as present if either the calculated eGFR was <30 mL/min/1.73m²; representing stage 4 to 5 CKD, or if the patient had a history of renal replacement therapy or renal transplantation as recorded on the data collection form. The most recent urine collection examining protein or albumin was recorded. The urine albumin result was used to derive the presence of microalbuminuria or macroalbuminuria.²² Systolic and diastolic blood pressures were recorded at the time of appointment in mmHg. BMI (kilogram/metre²) was calculated using measured weight (kg) and height (m) and the formula: weight / (height x height).

The number of glucose lowering therapies was reported in those with type 2 diabetes only, and calculated as the total number of prescribed medications from the following classes; Insulin, Acarbose, Glucagon like peptide 1 (GLP-1) receptor agonist, Glitazone, Sulphonylurea, Metformin, Dipeptidyl peptidase-4 (DPP-4) inhibitor and Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitors.

Anti-hypertensive therapy use was reported if any medications from the following classes were prescribed; angiotensin-converting enzyme (ACE) inhibitor, angiotensin II receptor blocker (ARB), beta blocker, thiazide, calcium channel blocker or other anti-hypertensive agent. Lipid

Table 1

Characteristics of patients participating in the Australian National Diabetes Audit (2011, 2013, 2015 and 2017), stratified by smoking status.

	Smoking status				p-value
	All % (N) n = 15,352	Never % (n) n = 8241	Past % (n) n = 5033	Current % (n) n = 2078	
Age (years) α	59.9 [46.6, 69.6]	59.1 [42.9, 69.7]	63.7 [54.3, 71.4]	52.7 [41.8, 62.2]	0.0001
Sex (male)	53.2 (8111)	43.2 (3533)	67.0 (3350)	59.6 (1228)	<0.0001
Diabetes type					<0.0001
Type 1	24.8 (3804)	28.2 (2325)	17.1 (861)	29.7 (618)	
Type 2	72.2 (11,087)	68.7 (5665)	80.2 (4034)	66.8 (1388)	
Other	3.0 (461)	3.1 (251)	2.7 (138)	3.5 (72)	
Diabetes duration α	13 [6, 21]	13 [7, 21]	14 [7, 21]	10 [4, 18]	0.0001
Diabetes management					<0.0001
Diet only	3.6 (552)	3.8 (316)	3.4 (169)	3.2 (67)	
Tablets and insulin	23.7 (3638)	23.4 (1931)	24.1 (1212)	23.8 (495)	
Tablets and non-insulin injectables	36.5 (5605)	39.4 (3245)	30.8 (1549)	39.0 (811)	
Insulin only	30.9 (4744)	28.3 (2332)	36.2 (1822)	28.4 (590)	
Other/unstated	5.3 (813)	5.1 (417)	5.6 (281)	5.5 (115)	
Insulin-treated	70.6 (10,675)	70.8 (5740)	70.3 (3489)	70.4 (1446)	0.803
Insulin duration (years) α^a	7 [2, 15]	8 [3, 15]	6 [2, 15]	6 [2, 15]	0.0001
Glycemic control					
HbA1c (%) α	7.9 [7.0, 9.0]	7.8 [6.9, 8.9]	7.9 [7.0, 9.0]	8.4 [7.2, 9.7]	0.0001
Severe hypoglycemia	8.7 (1286)	8.3 (654)	8.8 (425)	10.4 (207)	0.010
Number of glucose lowering therapies $\alpha \pm$	2 [1, 2]	2 [1, 2]	2 [1, 2]	2 [1, 2]	0.156
BMI α	30.4 [26.2, 35.5]	29.8 [25.7, 34.9]	31.7 [27.5, 36.7]	29 [24.7, 34.6]	0.0001
Complications					
Retinopathy	22.1 (2886)	21.5 (1520)	24.3 (1043)	19.0 (323)	<0.0001
Peripheral neuropathy	24.9 (3761)	21.2 (1721)	31.1 (1543)	24.4 (497)	<0.0001
Advanced CKD	7.4 (1092)	7.0 (556)	9.1 (442)	4.7 (94)	<0.0001
Microalbuminuria	28.4 (2737)	26.4 (1387)	31.8 (1004)	28.5 (346)	<0.0001
Macroalbuminuria	12.9 (1242)	11.1 (583)	14.7 (466)	15.9 (193)	<0.0001
Erectile dysfunction \times	29.5 (2220)	24.5 (814)	35.8 (1106)	27.0 (300)	<0.0001
Peripheral vascular disease	11.0 (1649)	7.7 (624)	15.5 (766)	12.8 (259)	<0.0001
Myocardial infarction	12.4 (1820)	8.8 (692)	18.6 (903)	11.3 (225)	<0.0001
Coronary artery revascularisation	13.1 (1936)	9.7 (771)	20.0 (981)	9.4 (184)	<0.0001
Stroke	6.2 (925)	5.1 (407)	8.3 (405)	5.6 (113)	<0.0001
Foot ulcer	8.2 (1215)	6.6 (520)	10.6 (516)	9.0 (179)	<0.0001
Lower limb amputation	3.0 (443)	2.2 (178)	4.0 (195)	3.5 (70)	<0.0001
Lipids					
Cholesterol α	4.2 [3.5, 5.0]	4.2 [3.6, 5.0]	4.0 [3.4, 4.8]	4.4 [3.6, 5.3]	0.0001
LDL α	2.1 [1.6, 2.8]	2.1 [1.6, 2.8]	2.0 [1.5, 2.6]	2.3 [1.7, 2.9]	0.0001
HDL α	1.1 [0.9, 1.4]	1.2 [1.0, 1.5]	1.1 [0.9, 1.4]	1.1 [0.9, 1.3]	0.0001
Triglycerides α	1.6 [1.0, 2.4]	1.5 [1.0, 2.2]	1.7 [1.1, 2.5]	1.7 [1.1, 2.7]	0.0001
Blood pressure					
Systolic BP β	130.8 (\pm 17.9)	130.3 (\pm 17.9)	132.5 (\pm 17.9)	128.2 (\pm 17.9)	0.980
Diastolic BP β	74.8 (\pm 10.7)	74.7 (\pm 10.6)	74.6 (\pm 10.7)	75.7 (\pm 11.0)	0.075
Antihypertensive therapy	64.7 (9501)	60.8 (4779)	75.4 (3650)	54.2 (1072)	<0.0001
Lipid lowering therapy	64.7 (9657)	60.8 (4851)	74.1 (3648)	57.5 (1158)	<0.0001

^a Insulin duration and SGLT2 inhibitor use were not available for 2011 and 2013 data. α median [interquartile range] reported, differences analysed with Kruskal Wallis test. β mean (standard deviation) reported, differences analysed with ANOVA. Number of glucose lowering therapies (\pm) includes the total number of medication classes of: insulin, acarbose GLP-1 agonist, glitazone, sulphonylurea, metformin, DPP-4 inhibitor and SGLT2 inhibitor in those with type 2 diabetes only. \times data collected and analysed in males only.

lowering therapy use was reported if any medications from the following classes were prescribed; statin, fibrate, ezetimibe or fish oil.

Microvascular and macrovascular complications were recorded as present if the patient reported having ever had the disease following direct questioning, or if it was documented as part of their past medical history. Presence of retinopathy, peripheral neuropathy, advanced CKD, erectile dysfunction (males only), peripheral vascular disease, myocardial infarction, coronary artery revascularisation (coronary artery bypass graft surgery (CABG)/angioplasty), cerebral stroke, foot ulceration and lower limb amputation was recorded by the treating specialist at the time of data collection.

2.4. Confounding variables

Pre-specified confounding variables included age (years), sex (male and female), diabetes type (type 1, type 2 and other or unknown type), diabetes duration (years), and ANDA data collection year (2011, 2013, 2015 and 2017).

2.5. Statistical analysis

Patients were categorised by smoking status: never smoker, past smoker or current smoker, and summarised descriptively for the pooled cohort. Categorical variables were presented as percentages and counts (n), and differences in subgroups were analysed using the Chi-square test. Continuous variables were presented as mean (standard deviation) or median (interquartile range (IQR)), and differences in subgroups analysed using Analysis of Variance (ANOVA – for normally distributed data) and Kruskal-Wallis test (for skewed data). Missing data were minimal for most variables, and below the selected cut-off of <20% for the dependent variable. Certain variables that required pre-performed investigations, had a higher level of missing data. No imputation was performed. Data regarding SGLT2 inhibitors were not available in the 2011 and 2013 audits (the data collection form is reviewed and updated each year for novel treatments).

Quantile (median) regression was used for non-normally distributed continuous outcome variables; HbA_{1c}, BMI, total cholesterol, LDL,

Table 2
The association of smoking status with glycemic and metabolic outcomes in Australian patients living with diabetes.

	Past smokers		Current smokers		Current smokers		Current smokers		Likelihood Ratio test (interaction of year)	Pairwise comparison of coefficient p-value
	Median difference (unadjusted)	p-value	Median difference (adjusted)	p-value	Median difference (unadjusted)	p-value	Median difference (adjusted)	p-value		
HbA _{1c} (%)	0.10 [0.03, 0.17]	0.004	0.14 [0.07, 0.21]	<0.0001	0.60 [0.51, 0.69]	<0.0001	0.49 [0.40, 0.59]	<0.0001	0.6542	<0.0001
BMI	1.91 [1.61, 2.21]	<0.0001	1.57 [1.27, 1.87]	<0.0001	-0.63 [-1.04, -0.22]	0.003	-0.78 [-1.18, -0.37]	<0.0001	0.4244	<0.0001
Cholesterol	-0.20 [-0.25, -0.15]	<0.0001	-0.06 [-0.11, -0.01]	0.043	0.20 [0.13, 0.27]	<0.0001	0.09 [0.02, 0.16]	0.018	0.1508	0.0003
LDL	-0.16 [-0.21, -0.11]	<0.0001	-0.07 [-0.12, -0.02]	0.004	0.16 [0.09, 0.23]	<0.0001	0.03 [-0.03, 0.10]	0.319	0.9323	0.0040
HDL	-0.10 [-0.11, -0.09]	<0.0001	-0.04 [-0.05, -0.02]	<0.0001	-0.10 [-0.11, -0.09]	<0.0001	-0.08 [-0.11, -0.06]	<0.0001	0.1782	0.0003
Triglycerides	0.20 [0.14, 0.26]	<0.0001	0.12 [0.08, 0.16]	<0.0001	0.20 [0.12, 0.29]	<0.0001	0.26 [0.20, 0.32]	<0.0001	0.2137	<0.0001
	Mean difference (unadjusted)	p-value	Mean difference (adjusted)	p-value	Mean difference (unadjusted)	p-value	Mean difference (adjusted)	p-value	Likelihood Ratio test (interaction of year)	Pairwise comparison of coefficient p-value
Systolic blood pressure	2.21 [1.58, 2.85]	<0.0001	-0.06 [-0.69, 0.58]	0.864	-2.09 [-2.96, -1.21]	<0.0001	-1.15 [-2.01, -0.29]	0.009	0.8794	0.0193
Diastolic blood pressure	-0.10 [-0.48, 0.28]	0.611	-0.15 [-0.53, 0.24]	0.462	1.01 [0.49, 1.53]	<0.0001	0.08 [-0.44, 0.60]	0.764	0.3665	0.4288
	Odds ratio (unadjusted)	p-value	Odds ratio (adjusted)	p-value	Odds ratio (unadjusted)	p-value	Odds ratio (adjusted)	p-value	Likelihood Ratio test (interaction of year)	Pairwise comparison of coefficient p-value
Severe hypoglycemia	1.07 [0.94, 1.21]	0.313	1.21 [1.05, 1.39]	0.008	1.29 [1.09, 1.52]	0.002	1.49 [1.25, 1.78]	<0.0001	0.0557	0.0284
Number of glucose lowering therapies	1.08 [0.99, 1.16]	0.058	1.08 [0.99, 1.17]	0.054	1.01 [0.91, 1.13]	0.825	1.03 [0.92, 1.16]	0.596	0.7785	0.4442
Antihypertensive therapy	1.98 [1.83, 2.15]	<0.0001	1.35 [1.22, 1.48]	<0.0001	0.77 [0.69, 0.85]	<0.0001	0.97 [0.86, 1.10]	0.648	0.0917	<0.0001
Lipid lowering therapy	1.85 [1.71, 2.00]	<0.0001	1.27 [1.16, 1.39]	<0.0001	0.87 [0.79, 0.97]	0.009	1.13 [1.00, 1.27]	0.045	0.2523	0.0721

Reference category is non-smokers. Adjusted for age (continuous), sex (male or female), diabetes type (type 1, type 2, other), diabetes duration (years) and year (2011, 2013, 2015, 2017) p-values significance set at 0.05/22(outcomes) = 0.002.

Past smokers




Fig. 1. The association between past smoking and diabetes complications, compared with never smoking. Adjusted analyses adjusted for age, sex, diabetes type, diabetes duration and study year.

HDL and triglycerides, and unadjusted and adjusted median differences were reported. Ordinal regression was used to assess the relationship between smoking status and the number of therapies, and unadjusted and adjusted Odds Ratios were reported. Linear regression was used for normally distributed continuous outcome variables; systolic and diastolic blood pressure, and unadjusted and adjusted mean differences were reported. Binary logistic regression was used to explore the relationship between smoking status and binary outcome variables: severe hypoglycemia, retinopathy, peripheral neuropathy, advanced CKD, microalbuminuria, macroalbuminuria, erectile dysfunction, peripheral

vascular disease, myocardial infarction, coronary artery revascularisation, stroke, foot ulceration, lower limb amputation, use of anti-hypertensive therapy and use of lipid lowering therapy, and unadjusted and adjusted Odds Ratios were reported. Multivariable models were performed for each outcome, adjusted for age, sex, diabetes type, diabetes duration and year of data collection; as these variables were determined a-priori to be clinically important confounders. The moderating effect of year of data collection was examined by including an interaction term between year and smoking on each outcome, and the likelihood ratio test was used to evaluate whether the inclusion of this term improved fit of the

Current smokers




Fig. 2. The association between current smoking and diabetes complications, compared with never smoking. Adjusted analyses adjusted for age, sex, diabetes type, diabetes duration and study year.

model. Due to the substantial number of outcome variables and to avoid the issue of multiplicity, a more stringent level of significance ($p < .002$) was used to determine statistical significance, using the Bonferroni method. All analyses were performed in Stata Statistical Software (StataCorp, College Station, Texas 77845, USA) version 14.0.

3. Results

3.1. Descriptive summary

Data from 19,374 patients were reviewed from the 2011, 2013, 2015 and 2017 ANDA-AQCA audits. Of those, 15,352 patients had a valid smoking status and were included in the analysis for this study. Characteristics of the study population are presented in Table 1. Median [IQR] age was 59.9 [46.6, 69.6] years and males represented 53.2% of patients. The median [IQR] duration of diabetes was 13 [6, 21] years. The largest proportion of patients (72.2%) had type 2 diabetes. Current and past smokers represented 46.3% of the study population. The median number and type of glucose lowering therapies including insulin was broadly similar among the smoking categories. Compared to never and past smokers, current smokers were less likely to report receiving antihypertensive or lipid lowering therapies ($p < .0001$ for both therapy categories).

The most frequently reported complications were erectile dysfunction among men (29.5%), microalbuminuria (28.4%), peripheral neuropathy (24.9%) and retinopathy (22.1%). The proportion of patients with complications (i.e. peripheral neuropathy, microalbuminuria, macroalbuminuria, erectile dysfunction, peripheral vascular disease, myocardial infarction, coronary artery revascularisation, stroke, foot ulcer, lower limb amputation and severe hypoglycemia) was higher among current and past smokers than never smokers (all p values $< .0001$).

3.2. The association between smoking status and clinical outcomes

The results of unadjusted and adjusted analyses (for age, sex, diabetes type, diabetes duration and study year) examining the relationship of smoking status with glycemic control, metabolic profile and microvascular and macrovascular complications are presented in Table 2, Fig. 1 and Fig. 2.

3.3. Glycemic and metabolic profile

The median HbA_{1c} was 0.49% higher among current smokers (median difference 0.49, [0.40, 0.59], $p < .0001$), and 0.14% higher among past smokers (0.14, [0.07, 0.21], $p < .0001$) when compared to never smokers. There was no relationship between smoking status and the number of glucose lowering therapies used. Current smokers (aOR = 1.49 [1.25, 1.78], $p < .0001$) had higher odds of severe hypoglycemia than never smokers.

Current smokers had a lower median BMI (-0.78 [$-1.18, -0.37$], $p < .0001$) and past smokers had a higher median BMI (1.57 [1.27, 1.87], $p < .0001$) than never smokers. Total cholesterol, LDL cholesterol and systolic and diastolic blood pressure differences between smoking groups were not significant. HDL cholesterol levels were 0.08 mmol/L ($-0.08, [-0.11, -0.06]$, $p < .0001$) lower in current smokers and 0.04 mmol/L ($-0.04, [-0.05, -0.02]$, $p < .0001$) lower in past smokers, compared to never smokers. Triglyceride levels were 0.26 mmol/L (0.26, [0.20, 0.32], $p < .0001$) higher in current smokers and 0.12 mmol/L (0.12 [0.08, 0.16], $p < .0001$) higher in past smokers, compared to never smokers.

3.4. Microvascular complications

Compared to never smokers, the odds of peripheral neuropathy were higher in current (aOR = 1.54 [1.36, 1.74], $p < .0001$) and past smokers

(aOR = 1.38 [1.26, 1.51], $p < .0001$). The odds of macroalbuminuria (aOR = 1.53 [1.28, 1.84], $p < .0001$) were also higher in current compared to never smokers. Smoking status was not significantly associated with retinopathy, microalbuminuria and advanced CKD.

3.5. Macrovascular complications

Current and past smokers had higher odds of myocardial infarction (aOR = 1.74 [1.47, 2.06] and aOR = 1.76 [1.57, 1.98]), cerebral stroke (aOR = 1.47 [1.18, 1.85] and aOR = 1.35 [1.16, 1.57]) and peripheral vascular disease (aOR = 2.50 [2.11, 3.00] and aOR = 1.75 [1.55, 1.97]), when compared to never smokers (all $p < .001$). In addition, past smokers (aOR = 1.70 [1.53, 1.91], $p < .0001$) had higher odds of having undergone coronary artery revascularisation procedures, when compared to never smokers.

3.6. Other complications

Both current and past smokers had higher odds of foot ulceration (aOR = 1.59 [1.32, 1.91] and aOR = 1.36 [1.19, 1.55]), lower limb amputation (aOR = 1.73 [1.28, 2.33] and aOR = 1.42 [1.14, 1.78]) and erectile dysfunction (aOR = 1.49 [1.26, 1.76] and aOR = 1.37 [1.22, 1.53]) when compared to never smokers (all $p < .0001$).

3.7. Annual trends (effect of study year)

The association of smoking status with glycemic control, metabolic risk factors and diabetic complications did not significantly change over the 6-year study interval.

4. Discussion

We explored the association between smoking status and glycemic control, metabolic risk factors and microvascular and macrovascular complications in over 15,000 Australian adults living with diabetes. We observed that current smoking was associated with worse glycemic control as demonstrated by a higher median HbA_{1c} and higher odds of severe hypoglycemia, despite this sub-group being on average younger and having had diabetes for a shorter period of time. Current and past smoking were also associated with higher odds of dyslipidaemia, peripheral neuropathy, erectile dysfunction, peripheral vascular disease, myocardial infarction, cerebral stroke, foot ulceration and lower limb amputation. The odds associated with current and past smoking were considerably higher for macrovascular, compared with microvascular complications.

The results of our study are consistent with the growing evidence of the detrimental effects of smoking in diabetes.^{14,16,23,24} Similarly, the long-standing associations seen between smoking and micro- and macrovascular complications^{25–27} have also been reported in more recent literature.^{28–31} We have built on this evidence by also reporting a significant association between current smoking and worse glycemic control and metabolic profile, and an increased risk of a range of diabetic complications among a large group of patients attending diabetes centres across Australia.

We observed that the prevalence of smoking in our cohort with diabetes (13.5%) was similar to that among the general Australian population (13.8%) in 2017–18.¹ This suggests suboptimal adherence to primary and/or secondary prevention recommendations on smoking cessation in this high-risk population. Furthermore, the potential for weight gain in the initial period of smoking cessation³² should not deter patients from making efforts given the substantial improvements in metabolic parameters,³³ and the lower risk of microvascular and macrovascular complications and mortality³⁴ that accompany smoking cessation. Given the ongoing high rates of smoking, assessment of tobacco use, and counselling or treatments that aid smoking cessation, as recommended by guidelines, should be considered as an imperative

for improving outcomes among people with diabetes.^{15,18} Further research on interventions that promote smoking cessation among people with diabetes would also be useful.

Among current smokers, treatment with antihypertensive or lipid lowering therapies was significantly lower despite their greater risk profile, whilst use of glucose lowering therapies was similar, compared to past and never smokers. This highlights the need for continued review and re-evaluation of clinical guidelines and optimal patient-specific targets, so that timely intensification of therapy occurs and clinical inertia is avoided.^{15,35}

A strength of the use of the ANDA data is that it provides information regarding a large population of patients with both type 1 and type 2 diabetes, throughout all states and territories of Australia. We believe these data describe for the first time the prevalence of smoking and its relationship with diabetic outcomes among an Australian population of individuals with diabetes. There are limitations to the use of the ANDA dataset. All data collected were cross-sectional in nature with no current linked follow up of the de-identified patients from one audit to another. In that setting, we are able to only discuss associations rather than causal interactions, and there is also no capacity to collect mortality data. However, there is scope to add linked longer-term assessments in future years, with the addition of a longitudinal component to the audit which was commenced with the 2019 ANDA AQCA data collection. There was a high prevalence of missing data for the albumin and lipid profile variables, therefore these variables should be interpreted with caution as a larger proportion of participants were excluded from their analysis, which has the potential to introduce selection bias for these outcomes. Another limitation is that a larger proportion of patients are from tertiary diabetes services rather than primary care practices, which may also introduce referral bias. More complicated patients with multiple complications tend to be referred for further specialist management, therefore our cohort may not be entirely comparable to the population with diabetes that is managed in general practice. There is also reliance on the patient or the healthcare worker to accurately complete the data collection form, as the de-identified data cannot be further independently validated, which may contribute to missed or incorrect diagnoses.

5. Conclusion

In an adult Australian population of patients with diabetes, current and past smoking was associated with worse glycaemic and lipid control, and higher odds of macrovascular and microvascular complications, when compared to never smoking. The prevalence of complications has not improved over recent years, even with the introduction of newer therapeutic agents. Despite this increased risk, smoking remains prevalent among the Australian population with diabetes. Smoking cessation should be a major focus of care among people with diabetes. This, together with addressing physician-patient- and healthcare-related factors that contribute to the lack of timely initiation and intensification of appropriate treatment, may help improve glycaemic and metabolic control and prevent or halt the progression of micro- and macrovascular complications.

The authors NS, MV, AE and SZ had full access to the data and take responsibility for the integrity of the data and accuracy of the analysis. All authors have read and approved the final manuscript.

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.jdiacomp.2020.107626>.

CRedit authorship contribution statement

N. Szwarcbard: Conceptualization, Methodology, Validation, Investigation, Writing - original draft, Writing - review & editing, Project administration. **M. Villani:** Conceptualization, Formal analysis, Data curation, Writing - review & editing. **A. Earnest:** Formal analysis, Writing - review & editing, Supervision. **J. Flack:** Writing - review & editing. **S.**

Andrikopoulos: Writing - review & editing. **N. Wischer:** Writing - review & editing. **G. Soldatos:** Writing - review & editing. **D. Gasevic:** Writing - review & editing, Supervision. **S. Zoungas:** Conceptualization, Methodology, Writing - review & editing, Supervision.

Declaration of competing interest

All authors have declared no conflicts of interest regarding this work.

Acknowledgements

We thank the patients and health professionals from the participating diabetes centres for their time and generous contributions to the Australian National Diabetes Audit.

Contributions

NS: study conception and design, review of literature, interpretation of data, critical discussion, drafting and revision of the manuscript. MV: study design, statistical analysis, interpretation of data, critical discussion, revision of the manuscript. AE: statistical analysis supervision, critical discussion, revision of the manuscript. JF, SA, NW and GS: revision of the manuscript. DG: interpretation of data, manuscript writing, critical revision of the manuscript. SZ study conception and design, interpretation of data, critical discussion, revision of manuscript and supervision of the project. The authors NS, MV, AE and SZ had full access to the data and take responsibility for the integrity of the data and accuracy of the analysis. All authors have read and approved the final manuscript.

Funding

The Commonwealth Department of Health and Ageing funds the Australian National Diabetes Audit. This research paper received no specific grant from any other funding agency in the public, commercial or not-for profit sectors.

Consent for publication

Not applicable.

Ethics approval

The Australian National Diabetes Audit has received ethics approval from the Monash Health Human Research Ethics Committee (Monash Health Reference: RES-17-0000-164L).

Data sharing statement

Applications for datasets generated and/or analysed during the current study may be considered by corresponding with the ANDA secretariat on reasonable request in line with research data enquiry procedures.

Part of this study has been presented during the 2019 Australasian Diabetes Congress (August 21st-23rd 2019), Sydney, Australia.

References

- 4364.0.55.001 - National Health Survey First Results, 2017-18. Australian Bureau of Statistics; 2018.
- Diabetes Australia: Diabetes in Australia [17/06/2019]. Available from: <https://www.diabetesaustralia.com.au/diabetes-in-australia>.
- Australian Institute of Health and Welfare. Diabetes snapshot, How many Australians have diabetes? 2018, July 24 Available from: <https://www.aihw.gov.au/reports/diabetes/diabetes-snapshot/contents/how-many-australians-have-diabetes>.
- Lee CM, Colagiuri R, Magliano DJ, Cameron AJ, Shaw J, Zimmet P, et al. The cost of diabetes in adults in Australia. *Diabetes Res Clin Pract* 2013;99:385-90.
- Australian Burden of Disease Study: impact and causes of illness and death in Australia 2015. Canberra, Australia: Australian Institute of Health and Welfare; 2019.
- WHO report on the global tobacco epidemic, 2017: monitoring tobacco use and prevention policies. World Health Organization Geneva, Switzerland. 2017.

7. Maddatu J, Anderson-Baucum E, Evans-Molina C. Smoking and the risk of type 2 diabetes. *Transl Res* 2017;184:101-7.
8. Xie XT, Liu Q, Wu J, Wakui M. Impact of cigarette smoking in type 2 diabetes development. *Acta Pharmacol Sin* 2009;30:784-7.
9. Targher G, Alberiche M, Zenere MB, Bonadonna RC, Muggeo M, Bonora E. Cigarette smoking and insulin resistance in patients with noninsulin-dependent diabetes mellitus. *J Clin Endocrinol Metab* 1997;82:3619-24.
10. Tweed JO, Hsia SH, Lutfy K, Friedman TC. The endocrine effects of nicotine and cigarette smoke. *Trends Endocrinol Metab* 2012;23:334-42.
11. Kapoor D, Jones TH. Smoking and hormones in health and endocrine disorders. *Eur J Endocrinol* 2005;152:491-9.
12. Pan A, Wang Y, Talaei M, Hu FB, Wu T. Relation of active, passive, and quitting smoking with incident type 2 diabetes: a systematic review and meta-analysis. *Lancet Diabetes Endocrinol* 2015;3:958-67.
13. Willi C, Bodenmann P, Ghali WA, Faris PD, Cornuz J. Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. *JAMA* 2007;298:2654-64.
14. The Health Consequences of Smoking-50 Years of Progress: A Report of the Surgeon General. Atlanta (GA): Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.
15. Standards of Medical Care in Diabetes—2019. American Diabetes Association. *DiabetesCare*. 2019;42(Supplement 1).
16. Pan A, Wang Y, Talaei M, Hu FB. Relation of smoking with total mortality and cardiovascular events among patients with diabetes mellitus: a meta-analysis and systematic review. *Circulation* 2015;132:1795-804.
17. Hirai FE, Moss SE, Klein BE, Klein R. Severe hypoglycemia and smoking in a long-term type 1 diabetic population: Wisconsin epidemiologic study of diabetic retinopathy. *Diabetes Care* 2007;30:1437-41.
18. General practice management of type 2 diabetes: 2016–18. East Melbourne, Vic: The Royal Australian College of General Practitioners.; 2016.
19. Australian National Diabetes Audit - National Association of Diabetes Centres Available from: <https://nadc.net.au/anda/>.
20. Danek E, Earnest A, Wischer N, Andrikopoulos S, Pease A, Nanayakkara N, et al. Risk-adjustment of diabetes health outcomes improves the accuracy of performance benchmarking. *Sci Rep* 2018;8:10261.
21. The Pathology Service of St Vincent's Hospital - Estimation of the Glomerular Filtration Rate. Available from: <http://www.syddpath.stvincents.com.au/eGFR.htm>.
22. Heerspink H, H Brantsma A, de Zeeuw D, Bakker S, E de Jong P, T Gansevoort R. Albuminuria Assessed From First-Morning-Void Urine Samples Versus 24-Hour Urine Collections as a Predictor of Cardiovascular Morbidity and Mortality 2008. 897–905 p.
23. Sliwinska-Mosson M, Milnerowicz H. The impact of smoking on the development of diabetes and its complications. *Diab Vasc Dis Res* 2017;14:265-76.
24. Kar D, Gillies C, Zaccardi F, Webb D, Seidu S, Tesfaye S, et al. Relationship of cardio-metabolic parameters in non-smokers, current smokers, and quitters in diabetes: a systematic review and meta-analysis. *Cardiovasc Diabetol* 2016;15:158.
25. Chaturvedi N, Stephenson JM, Fuller JH. The relationship between smoking and microvascular complications in the EURODIAB IDDM complications study. *Diabetes Care* 1995;18:785-92.
26. Morrish NJ, Stevens LK, Fuller JH, Jarrett RJ, Keen H. Risk factors for macrovascular disease in diabetes mellitus: the London follow-up to the WHO multinational study of vascular disease in diabetics. *Diabetologia* 1991;34:590-4.
27. Nilsson PM, Cederholm J, Eeg-Olofsson K, Eliasson B, Zethelius B, Fagard R, et al. Smoking as an independent risk factor for myocardial infarction or stroke in type 2 diabetes: a report from the Swedish National Diabetes Register. *Eur J Cardiovasc Prev Rehabil* 2009;16:506-12.
28. Gedebjerg A, Almdal TP, Berencsi K, Rungby J, Nielsen JS, Witte DR, et al. Prevalence of micro- and macrovascular diabetes complications at time of type 2 diabetes diagnosis and associated clinical characteristics: a cross-sectional baseline study of 6958 patients in the Danish DD2 cohort. *J Diabetes Complications* 2018;32:34-40.
29. Jiang N, Huang F, Zhang X. Smoking and the risk of diabetic nephropathy in patients with type 1 and type 2 diabetes: a meta-analysis of observational studies. *Oncotarget* 2017;8:93209-18.
30. Tracey ML, McHugh SM, Fitzgerald AP, Buckley CM, Canavan RJ, Kearney PM. Risk factors for macro- and microvascular complications among older adults with diagnosed type 2 diabetes: findings from the Irish longitudinal study on ageing. *J Diabetes Res* 2016;2016:5975903.
31. Uruska A, Araszkiwicz A, Uruski P, Zozulinska-Ziolkiewicz D. Higher risk of microvascular complications in smokers with type 1 diabetes despite intensive insulin therapy. *Microvasc Res* 2014;92:79-84.
32. Tian J, Venn A, Otahal P, Gall S. The association between quitting smoking and weight gain: a systematic review and meta-analysis of prospective cohort studies. *Obes Rev* 2015;16:883-901.
33. Voulgari C, Katsilambros N, Tentolouris N. Smoking cessation predicts amelioration of microalbuminuria in newly diagnosed type 2 diabetes mellitus: a 1-year prospective study. *Metabolism* 2011;60:1456-64.
34. Liu G, Hu Y, Zong G, Pan A, Manson JE, Rexrode KM, et al. Smoking cessation and weight change in relation to cardiovascular disease incidence and mortality in people with type 2 diabetes: a population-based cohort study. *Lancet Diabetes Endocrinol* 2020;8:125-33.
35. Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetologia* 2018;61:2461-98.